Regeneron’s fianlimab lung test approaches
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
